Nisha Bansal1, David V Glidden2, Rajnish Mehrotra2, Raymond R Townsend3, Jordana Cohen3, Lori Linke4, Farshad Palad5, Hannah Larson4, Chi-Yuan Hsu5. 1. Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA. Electronic address: nbansal@nephrology.washington.edu. 2. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA. 3. Division of Nephrology, University of Pennsylvania, Philadelphia, PA. 4. Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA. 5. Division of Nephrology, University of California, San Francisco, San Francisco, CA.
Abstract
RATIONALE & OBJECTIVE: Observational studies have reported a U-shaped association between blood pressure (BP) before a hemodialysis session and death. In contrast, because a linear association between out-of-dialysis-unit BP and death has been reported, home BP may be a better target for treatment. To test the feasibility of this approach, we conducted a pilot trial of treating home versus predialysis BP in hemodialysis patients. STUDY DESIGN: A 4-month, parallel, randomized, controlled trial. SETTINGS & PARTICIPANTS: 50 prevalent hemodialysis patients in San Francisco and Seattle. Participants were randomly assigned using 1:1 block randomization, stratified by site. INTERVENTIONS: To target home systolic BP (SBP) of 100-<140 mm Hg versus predialysis SBP of 100-<140mm Hg. Home and predialysis SBPs were ascertained every 2 weeks. Dry weight and BP medications were adjusted to reach the target SBP. OUTCOMES: Primary outcomes were feasibility, adherence, safety. and tolerability. RESULTS: 50 of 70 (71%) patients who were approached agreed to participate. All enrollees completed the study except for 1 who received a kidney transplant. In the home BP treatment group, adherence to obtaining/reporting home BP was 97.4% (and consistent over the 4 months). There was no increased frequency of high (defined as SBP>200mm Hg; 0.2% vs 0%) or low (defined as<90mm Hg; 1.8% vs 1.2%) predialysis BP readings in the home versus predialysis treatment arms, respectively. However, participants in the home BP arm had higher frequency of fatigue (32% vs 16%). LIMITATIONS: Small sample size. CONCLUSIONS: This pilot trial demonstrates feasibility and high adherence to home BP measurement and treatment in hemodialysis patients. Larger trials to test the long-term feasibility, efficacy, and safety of home BP treatment in hemodialysis patients should be conducted. FUNDERS: National Institutes of Health, Satellite Healthcare, and Northwest Kidney Centers. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03459807.
RATIONALE & OBJECTIVE: Observational studies have reported a U-shaped association between blood pressure (BP) before a hemodialysis session and death. In contrast, because a linear association between out-of-dialysis-unit BP and death has been reported, home BP may be a better target for treatment. To test the feasibility of this approach, we conducted a pilot trial of treating home versus predialysis BP in hemodialysis patients. STUDY DESIGN: A 4-month, parallel, randomized, controlled trial. SETTINGS & PARTICIPANTS: 50 prevalent hemodialysis patients in San Francisco and Seattle. Participants were randomly assigned using 1:1 block randomization, stratified by site. INTERVENTIONS: To target home systolic BP (SBP) of 100-<140 mm Hg versus predialysis SBP of 100-<140mm Hg. Home and predialysis SBPs were ascertained every 2 weeks. Dry weight and BP medications were adjusted to reach the target SBP. OUTCOMES: Primary outcomes were feasibility, adherence, safety. and tolerability. RESULTS: 50 of 70 (71%) patients who were approached agreed to participate. All enrollees completed the study except for 1 who received a kidney transplant. In the home BP treatment group, adherence to obtaining/reporting home BP was 97.4% (and consistent over the 4 months). There was no increased frequency of high (defined as SBP>200mm Hg; 0.2% vs 0%) or low (defined as<90mm Hg; 1.8% vs 1.2%) predialysis BP readings in the home versus predialysis treatment arms, respectively. However, participants in the home BP arm had higher frequency of fatigue (32% vs 16%). LIMITATIONS: Small sample size. CONCLUSIONS: This pilot trial demonstrates feasibility and high adherence to home BP measurement and treatment in hemodialysis patients. Larger trials to test the long-term feasibility, efficacy, and safety of home BP treatment in hemodialysis patients should be conducted. FUNDERS: National Institutes of Health, Satellite Healthcare, and Northwest Kidney Centers. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03459807.
Authors: Matthew A Roberts; Helen L Pilmore; Andrew M Tonkin; Amit X Garg; Elaine M Pascoe; Sunil V Badve; Alan Cass; Francesco L Ierino; Carmel M Hawley Journal: Am J Kidney Dis Date: 2012-06-15 Impact factor: 8.860
Authors: Tobias Breidthardt; James O Burton; Aghogho Odudu; Mohamed Tarek Eldehni; Helen J Jefferies; Christopher W McIntyre Journal: Clin J Am Soc Nephrol Date: 2012-07-19 Impact factor: 8.237
Authors: Bruce M Robinson; Lin Tong; Jinyao Zhang; Robert A Wolfe; David A Goodkin; Roger N Greenwood; Peter G Kerr; Hal Morgenstern; Yun Li; Ronald L Pisoni; Rajiv Saran; Francesca Tentori; Tadao Akizawa; Shunichi Fukuhara; Friedrich K Port Journal: Kidney Int Date: 2012-06-20 Impact factor: 10.612
Authors: Jula K Inrig; Christopher Molina; Kristin D'Silva; Catherine Kim; Peter Van Buren; Jason D Allen; Robert Toto Journal: Am J Kidney Dis Date: 2014-12-17 Impact factor: 8.860
Authors: James O Burton; Helen J Jefferies; Nicholas M Selby; Christopher W McIntyre Journal: Clin J Am Soc Nephrol Date: 2009-04-08 Impact factor: 8.237
Authors: Eve A Kerr; Brian J Zikmund-Fisher; Mandi L Klamerus; Usha Subramanian; Mary M Hogan; Timothy P Hofer Journal: Ann Intern Med Date: 2008-05-20 Impact factor: 25.391
Authors: S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler Journal: Lancet Date: 1990-03-31 Impact factor: 79.321
Authors: Dana C Miskulin; Huan Jiang; Ambreen Gul; V Shane Pankratz; Susan S Paine; Jennifer J Gassman; Manisha Jhamb; Raymond Y Kwong; Lavinia Negrea; David W Ploth; Saeed Kamran Shaffi; Antonia M Harford; Philip G Zager Journal: Am J Kidney Dis Date: 2021-06-16 Impact factor: 8.860